Elsevier

Human Pathology

Volume 30, Issue 7, July 1999, Pages 879-880
Human Pathology

Correspondence
Letter to the editor

https://doi.org/10.1016/S0046-8177(99)90153-3Get rights and content

References (2)

  • JI Epstein et al.

    The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder

    Am J Surg Pathol

    (1998)
  • Mostofi FK, Davis CJ, Sesterhenn IA: Histological typing of urinary bladder tumours. International histological...

Cited by (31)

  • Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes

    2015, Redox Biology
    Citation Excerpt :

    Parameters registered were date of diagnosed tumor recurrences, progress in grade/stage, development of nodal or distant metastases, type of therapy and cause of death. For grading the WHO1999 malignancy-grading system [14] was used and tumor stage was assessed according to a modified TNM system suggested by Hall and Prout [15]. Venous blood (normal tissue) was collected at a later time point and was available for 359 patients, who were genotyped for the NOS2 promoter microsatellite (CCTTT)n polymorphism, the NOS3 promoter polymorphism rs2070744 (-786T>C), and the NOS3 exon 7 polymorphism rs1799983 (Glu298Asp) [8,12].

  • Effect of laminin 332 on motility and invasion in bladder cancer

    2013, Kaohsiung Journal of Medical Sciences
    Citation Excerpt :

    Resected tissues were fixed in 10% formalin and embedded in paraffin. Histological type and grade, and disease stage were based on both the WHO classification criteria [20] and the TNM system. Clinical and pathological staging were done using 2002 TNM (tumor, lymph node, and metastasis) classification.

  • Polymorphisms in nitric-oxide synthase 3 may influence the risk of urinary-bladder cancer

    2011, Nitric Oxide - Biology and Chemistry
    Citation Excerpt :

    Tumor stage was assessed according to a modified TNM system suggested by Hall and Prout [28]. The WHO 1999 malignancy grading system [29] was used for tumor grading. We have a 5-year clinical follow-up for 95% of all patients in the cohort.

  • The (CCTTT)n microsatellite polymorphism in the nitric oxide synthase 2 gene may influence bladder cancer pathogenesis

    2010, Journal of Urology
    Citation Excerpt :

    Tumor stage was assessed according to the Hall and Prout modified TNM system.21 For tumor grading we used the WHO 1999 malignancy grading system.22 The 164 population controls23 were from the same geographic area as patients with bladder cancer and most were white.

  • Clinical outcome of primary versus secondary bladder carcinoma in situ

    2010, Journal of Urology
    Citation Excerpt :

    To analyze the response to BCG we excluded from study 48 patients who progressed before BCG therapy and 36 missing the date of BCG therapy, leaving 182 with primary and 210 with secondary CIS available for analysis. Diagnosis was based on the UICC TNM system and graded according to the 1998 WHO/International Society of Urological Pathology grading system of bladder urothelial neoplasms.12 We reviewed the medical records for clinical information on patient characteristics.

View all citing articles on Scopus

Ferran Algaba, William C. Allsbrook, Alberto G. Ayala, Michael J. Becich, Antonio L. Beltrán, Liliane Boccon-Gibod, David G. Bostwick, Christer Busch, Charles J. Davis, John N. Eble, Christopher S. Foster, Masakuni Furusato, David J. Grignon, Peter A. Humphrey, Elia A. Ishak, Sonny L. Johansson, Edward C. Jones, Leopold G. Koss, Howard S. Levin, William M. Murphy, Robert O. Petersen, Andrew Renshaw, Jae Y. Ro, Jeffrey R. Ross, Isabel A. Sesterhenn, John R. Srigley, Sueli Suzigan, John B. Tomaszewski, Patricia Troncoso, Lawrence D. True, Mark A. Weis, Thomas M. Wheeler, Robert H. Young

View full text